Fate Therapeutics Inc

NASDAQ:FATE   3:59:53 PM EDT
32.90
-3.16 (-8.76%)
Earnings Announcements

Fate Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/03/2022 21:35 GMT
Fate Therapeutics Inc (FATE) - Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress.
Revenue Was $18.5 Million for Q2 of 2022.
Qtrly Net Loss per Common Share, Basic and Diluted $0.79.
Q2 Earnings per Share View $-0.83, Revenue View $12.9 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $14.98 Million
Adjusted EPS is expected to be -$0.89

Next Quarter Revenue Guidance is expected to be $15.2 Million
Next Quarter EPS Guidance is expected to be -$0.94

More details on our Analysts Page.